SCHEDULE 13D/A: Perceptive Advisors Updates Nautilus Biotechnology Stake and Board Representation

Perceptive Advisors has filed an amended Schedule 13D, disclosing an updated beneficial ownership of 10.1% in Nautilus Biotechnology, Inc. and the departure of Michael Altman from the company's Board of Directors.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively reported beneficial ownership of 12,815,113 shares of Nautilus Biotechnology, Inc. common stock.
• This beneficial ownership represents 10.1% of Nautilus Biotechnology's outstanding common stock.
• The reported ownership includes 220,902 shares underlying stock options granted to Michael Altman.
• Percentages are calculated based on 126,148,469 outstanding shares of Common Stock as of April 22, 2025.
• Michael Altman, a Managing Director of Perceptive Advisors, ceased serving on Nautilus Biotechnology's Board of Directors on June 20, 2025, following the expiration of his term.
• Mr. Altman did not stand for re-election at the Issuer's 2025 Annual Meeting of Stockholders.
• Perceptive Life Sciences Master Fund, Ltd. is entitled to receive director compensation related to Mr. Altman's board service through a partial management fee offset.

Sentiment

Score: 5

Explanation: The filing reports a routine board member departure due to term expiration and an updated beneficial ownership stake. There are no explicit positive or negative financial or operational disclosures, nor any contentious events.

Positives

• Perceptive Advisors, a significant institutional investor, maintains a substantial 10.1% stake in Nautilus Biotechnology, indicating continued investment interest.
• The departure of Michael Altman from the board appears to be a routine expiration of term and decision not to seek re-election, rather than a contentious event.

Negatives

• No explicit negatives are stated in the filing.

Risks

• No specific risks are mentioned in this Schedule 13D amendment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Nautilus Biotechnology's future operations or financial performance.

Industry Context

This Schedule 13D amendment primarily concerns changes in beneficial ownership and board representation for Nautilus Biotechnology, Inc. It does not provide information that allows for a direct analysis of broader industry trends or competitive landscape.

Comparison to Industry Standards

• Not applicable, as this filing primarily details changes in beneficial ownership and board composition rather than operational or financial results that can be benchmarked against industry standards or specific comparable companies/projects.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• The Perceptive Life Sciences Master Fund, Ltd. has the right to receive director compensation provided in respect of Mr. Altman's board service through a partial management fee offset.

Stakeholder Impact

• Shareholders: The departure of a board member representing a significant institutional investor could be noted, though the filing suggests a non-contentious exit. The continued high ownership percentage by Perceptive entities indicates ongoing investment interest.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by the information in this filing.

Next Steps

• No specific future actions or milestones are mentioned in this filing.

Key Dates

Keywords

Nautilus Biotechnology, Perceptive Advisors, Schedule 13D, Beneficial Ownership, Board of Directors, Michael Altman, Common Stock, SEC Filing, Institutional Investor, Biotechnology